CN101129391B - Medicament for eliminating OH free radical - Google Patents
Medicament for eliminating OH free radical Download PDFInfo
- Publication number
- CN101129391B CN101129391B CN2007101539090A CN200710153909A CN101129391B CN 101129391 B CN101129391 B CN 101129391B CN 2007101539090 A CN2007101539090 A CN 2007101539090A CN 200710153909 A CN200710153909 A CN 200710153909A CN 101129391 B CN101129391 B CN 101129391B
- Authority
- CN
- China
- Prior art keywords
- glycosides
- free radical
- medicine
- catalpol
- deoxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug to remove OH free radical, which comprises one of the following parts: salidroside, 6-deoxycatalpol, gluroside, bartsioside, Tubuloside A and cistantubuloside A. The invention removes OH free radical in the human body to delay senescence, which modifies the action of study and memory.
Description
Technical field:
The present invention relates to a kind of medicine of the OH of removing free radical.
Background technology:
Under normal circumstances, the intravital free radical of people is to be among the dynamic equilibrium of continuous generation and removing.Free radical is the effective system of defense of body, then can bring adverse effect to the vital movement of body as the free radical that can not keep certain level.But free-radical generating too much or removed slowly, and it can cause the various damages of body in molecular level, cellular level and histoorgan level by attacking life macromolecule material and various cell, and the senescence process of acceleration body also brings out various diseases.
Known medicine with delaying human body caducity process all is some Chinese crude drugs mostly at present, as: Fructus Lycii, Ganoderma, Flos Lonicerae, Radix Glycyrrhizae, Radix Paeoniae Rubra, curculigoside, Pericarpium Citri grandis, Herba Leonuri, Bulbus Lilii, Radix et Caulis Opuntiae Dillenii, Radix Bupleuri, Rhizoma Chuanxiong, Radix Puerariae etc., the effect of certain delaying human body caducity process is all arranged according to record, but all be to be familiar with by people generally with the form of Chinese herbal medicine, because its active constituent content is very low in concrete the use, and the composition that contains other a large amount of effects, thereby effect is bad in actual use.
Summary of the invention:
The purpose of this invention is to provide a kind of active constituent content height, it is few to contain other impurity, can remove human body OH free radical well, and then the medicine of delaying human body caducity process.
Medicine of the present invention is by at least a composition the in the following material:
Rhodioside (Salidroside), 6-deoxidation catalpol (6-deoxycatalpol), lattice Shandong glycosides (Gluroside), Bath glycosides (Bartsioside), pipe flower glycosides A (Tubuloside A), Cistanche Tubulosa glycosides A (Cistantubuloside A), boschnaloside A (Tubuloside A).
As further preferred version, above-mentioned medicine is:
Wherein at least a of rhodioside (Salidroside), 6-deoxidation catalpol (6-deoxycatalpol), lattice Shandong glycosides (Gluroside), Bath glycosides (Bartsioside), Cistanche Tubulosa glycosides A (Cistantubuloside A).
As further preferred version, above-mentioned medicine is:
Wherein at least a of 6-deoxidation catalpol (6-deoxycatalpol), lattice Shandong glycosides (Gluroside), Bath glycosides (Bartsioside).
As further preferred version, above-mentioned medicine is made of the single material in lattice Shandong glycosides (Gluroside).
Medicine of the present invention has the ability of good removing human body OH free radical, can the delaying human body caducity process.
It below is pharmacological tests of the present invention
Reagent: dimethyl pyrrole azone (DMPO), available from U.S. Sigma company, use activated carbon purification before using, make it not have the paramagnetic signal.
Key instrument: the electron paramagnetic resonance instrument ESP2300 type of German Bruker company.
Experimental technique:
OH radical generating system: get distilled water, 400 mmol/L Fe
2NH
3SO
4, lmmol/L DMPO, 6%H
2O
2More than 4 kinds of reagent respectively get 5 μ l and squeeze into the EP pipe, in the quartz capillary of packing into immediately behind the mixing.Add sample protection testing tube then, put into the resonator cavity of EPR spectrometer in the lump and measure, sample replaces distilled water with sample liquid during the test sample product in contrast, and all the other are the same, measurement result in 3min.
EPR test parameter: central magnetic field (CF): 3460G; Sweep length (SW): 100G; Sweep time (ST); 60S; Modulation amplitude (MA): 210G; Modulating frequency (MF): 100KHz; Microwave frequency: (MF) 91671GHz; Microwave power (MP): 20mW; Probe temperature (T): room temperature.
The preparation of sample liquid: the size of molecular weight per sample, it is an amount of to get a certain amount of specimen, add an amount of distilled water, the concentration that makes into sample is 5mmol/L, press the described method of OH radical generating system, measure EPR spectrum signal intensity with the electronics EPR spectrometer, calculate free radical scavenging activity, the results are shown in Table 1 with above-mentioned formula.
Result of the test: table 1, tried the scavenging action n=2 of thing to free radical scavenging activity
| Group | Free radical scavenging activity (5mmol/L) |
| Salidroside, rhodioside | 31.71 |
| 6-deoxycatalpol, 6-deoxidation catalpol | 58.54 |
| Gluroside, lattice Shandong glycosides | 90.24 |
| Bartsioside, the Bath glycosides | 65.85 |
| Tubuloside A, boschnaloside A | 12.20 |
| Cistantubuloside A Cistanche Tubulosa glycosides A | 41.46 |
From the table the result as can be seen: the lattice Shandong external free radical scavenging activity of glycosides is the highest, and boschnaloside A is minimum, and other several phenethyl alcohol glycoside compounds all have external free radical scavenging effect in various degree.
The specific embodiment:
Embodiment 1 ~ 20: table 2
Embodiment 21 ~ 45: table 3
Embodiment 46 ~ 70: table 4
Claims (5)
1. remove application in the medicine of OH free radical as unique active component in preparation by at least a among 6-deoxidation catalpol, lattice Shandong glycosides, Bath glycosides, boschnaloside A, the Cistanche Tubulosa glycosides A for one kind.
2. purposes according to claim 1 is characterized in that described chemical compound is by at least a composition the among 6-deoxidation catalpol, lattice Shandong glycosides, Bath glycosides, the Cistanche Tubulosa glycosides A.
3. purposes according to claim 1 is characterized in that described chemical compound is by at least a composition the in 6-deoxidation catalpol, lattice Shandong glycosides, the Bath glycosides.
4. purposes according to claim 1 is characterized in that described chemical compound is made of lattice Shandong glycosides list material.
5. the application of compositions in the medicine of preparation removing OH free radical is characterized in that also containing rhodioside except that containing the described chemical compound of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101539090A CN101129391B (en) | 2007-09-12 | 2007-09-12 | Medicament for eliminating OH free radical |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101539090A CN101129391B (en) | 2007-09-12 | 2007-09-12 | Medicament for eliminating OH free radical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101129391A CN101129391A (en) | 2008-02-27 |
| CN101129391B true CN101129391B (en) | 2010-09-29 |
Family
ID=39126901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101539090A Expired - Fee Related CN101129391B (en) | 2007-09-12 | 2007-09-12 | Medicament for eliminating OH free radical |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101129391B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103622980A (en) * | 2013-12-12 | 2014-03-12 | 宁夏医科大学 | Application of cistanche phenylethanoid glycoside compound to preparation of drugs for treating osteoporosis and drug composition containing cistanche phenylethanoid glycoside compound |
| CN107739398A (en) * | 2017-10-19 | 2018-02-27 | 焦作大学 | A kind of propionating catalpol derivatives and its preparation method and application |
| CN108912183B (en) * | 2018-07-06 | 2020-09-18 | 河南中医药大学 | Catalpol derivative acylated with croton and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306816A (en) * | 2000-02-03 | 2001-08-08 | 上海家化联合股份有限公司 | Skin wrinkle resisting composition |
| CN1379036A (en) * | 2002-05-10 | 2002-11-13 | 北京大学药学院 | Phenylethanol boschnaloside compounds |
-
2007
- 2007-09-12 CN CN2007101539090A patent/CN101129391B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306816A (en) * | 2000-02-03 | 2001-08-08 | 上海家化联合股份有限公司 | Skin wrinkle resisting composition |
| CN1379036A (en) * | 2002-05-10 | 2002-11-13 | 北京大学药学院 | Phenylethanol boschnaloside compounds |
Non-Patent Citations (8)
| Title |
|---|
| Muteliefu Gulinuer et al.Effect of Cistanoside Compounds on Oxidative StressandImmunity.journal of chinese pharmaceutical sciences10 3.2001,10(3),157-160. |
| Muteliefu Gulinuer et al.Effect of Cistanoside Compounds on Oxidative StressandImmunity.journal of chinese pharmaceutical sciences10 3.2001,10(3),157-160. * |
| 王晓雯等.肉苁蓉总甙对小鼠组织的抗氧化作用.中国中药杂志23 9.1998,23(9),554-555. |
| 王晓雯等.肉苁蓉总甙对小鼠组织的抗氧化作用.中国中药杂志23 9.1998,23(9),554-555. * |
| 王晓雯等.肉苁蓉总苷体外清除自由基及对OH.引发的DNA损伤的保护作用.中国药学杂志36 1.2001,36(1),第29-32页. |
| 王晓雯等.肉苁蓉总苷体外清除自由基及对OH.引发的DNA损伤的保护作用.中国药学杂志36 1.2001,36(1),第29-32页. * |
| 蔡溱等.红景天苷及其衍生物体外清除自由基作用的研究.中国现代应用药学杂志22 2.2005,22(2),第11页第2.3结果部分. |
| 蔡溱等.红景天苷及其衍生物体外清除自由基作用的研究.中国现代应用药学杂志22 2.2005,22(2),第11页第2.3结果部分. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101129391A (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taborsky et al. | Identification of potential sources of thymoquinone and related compounds in Asteraceae, Cupressaceae, Lamiaceae, and Ranunculaceae families | |
| JP2009256244A (en) | Claudin production promoter, occludin production promoter and skin barrier function-improving agent | |
| CN101129391B (en) | Medicament for eliminating OH free radical | |
| CN109730359A (en) | Triterpene compound in a kind of adiantum cpilus-veneris and preparation method thereof and the application in electronic cigarette | |
| CN101966212A (en) | Preparation method and use of Syringa pubescens bark extract | |
| CN101637500B (en) | Milk veteh, oleaster, walnut green husk and worm grass-containing health wine and effect thereof | |
| Paul et al. | Analgesic activity of methanol extract of Plumbago indica (L.) by acetic acid induced writhing method | |
| CN113018333A (en) | Extraction method of cistanche tubulosa | |
| Reanmongkol et al. | Anti-allergic and antioxidative activities of some compounds from Thai medicinal plants | |
| CN108125881B (en) | Anti-aging composition containing peach blossom extract and application thereof | |
| CN102455316A (en) | Method for measuring anti-oxidation activities of Chinese medicaments | |
| CN101396492A (en) | Quality control method for toxin ingredient, yunaconitine in Yuannan Hongyao capsule | |
| Chaudhuri et al. | Phytochemical composition of the extracts from Iresine herbstii and its therapeutic use via antioxidant and cytotoxic potential by multiple in vitro assays | |
| KR20150020192A (en) | Pharmaceutical composition containing human cyclooxygenase and doxorubicin or doxorubicin analogue, preparation method therefor and use thereof in preparing drugs | |
| CN1276760C (en) | Chinese medicine composition and its preparing method | |
| Ghauri et al. | In vitro Anti-ulcer potential of Raphanus sativus L. seeds | |
| CN106511154A (en) | Peach kernel extract and application thereof | |
| Fageyinbo et al. | Anti-inflammatory Effect of Hydroethanol Leaf Extract of Mitragyna stipulosa | |
| Choudhary | In vitro antioxidant studies of the ethanolic extract of Tephrosia purpurea L. | |
| CN111888290A (en) | Cinnamon bark extract and preparation method and application thereof | |
| Kakrani et al. | Experimental evaluation of anthelmintic and purgative activity of Myrsine africana fruits | |
| CN102205083B (en) | Xanthine oxidase inhibitor for treating gout and preparation method thereof | |
| Udegbunam et al. | Anti-inflammatory and anti-oxidant effects of Sterculia tragacantha fractions in mice | |
| CN118512522B (en) | Composition, preparation method and application thereof in preparation of products with caries preventing effect | |
| Sharma et al. | PHYSICOCHEMICAL AND PHYTOCHEMICAL SCREENING OF FLOWERS EXTRACT OF AERVA LANATA LINN. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100929 Termination date: 20110912 |